Literature DB >> 8398224

Recruitment for phase I of the trials of hypertension prevention.

S Satterfield1, N O Borhani, P Whelton, L Goodwin, C Brinkmann, J Charleston, B W Corkery, L Dolan, H Hataway, S Hertert.   

Abstract

Phase I of the Trials of Hypertension Prevention was a multicenter, randomized, controlled trial designed to determine the efficacy of seven nonpharmacologic interventions in reducing blood pressure among persons with high-normal diastolic blood pressure. The initial goal for recruitment was to enroll 2,100 participants over a nine-month period. The two major strategies for reaching potential participants were direct mailings and work site screenings. The yield from the first screening visit to randomization was 13% overall, with clinic-specific yields ranging from 4.5% to 31.7%. After five months of recruitment, approximately 60% of the goal for that point in the recruitment timetable had been randomized. Clinical centers falling short of their goals at that time altered their recruitment strategies and intensified their efforts, and centers that had exceeded their goals recruited additional participants. As a result, 2,182 participants, or 104% of the goal for recruitment, were randomized over a 13-month period. Those clinics using a cohort, or wave, type of enrollment were most successful in achieving their recruitment goals within the prescribed timetable.

Entities:  

Mesh:

Year:  1993        PMID: 8398224

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  4 in total

Review 1.  Omega 3 fatty acids for prevention and treatment of cardiovascular disease.

Authors:  L Hooper; R L Thompson; R A Harrison; C D Summerbell; H Moore; H V Worthington; P N Durrington; A R Ness; N E Capps; G Davey Smith; R A Riemersma; S B J Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

2.  Evaluation of a mass mailing recruitment strategy to obtain a community sample of women for a clinical trial of an incontinence prevention intervention.

Authors:  Kassandra L Messer; A Regula Herzog; Julia S Seng; Carolyn M Sampselle; Ananias C Diokno; T E Raghunathan; Sandra H Hines
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

3.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-11-30

Review 4.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Authors:  Asmaa S Abdelhamid; Tracey J Brown; Julii S Brainard; Priti Biswas; Gabrielle C Thorpe; Helen J Moore; Katherine Ho Deane; Fai K AlAbdulghafoor; Carolyn D Summerbell; Helen V Worthington; Fujian Song; Lee Hooper
Journal:  Cochrane Database Syst Rev       Date:  2018-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.